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Abstract: Diabetic cardiomyopathy (DCM), although a distinct clinical entity, is also a part 
of the diabetic atherosclerosis process. It may be independent of the coexistence of ischemic 
heart disease, hypertension, or other macrovascular complications. Its pathological substrate is 
  characterized by the presence of myocardial damage, reactive hypertrophy, and   intermediary 
fibrosis, structural and functional changes of the small coronary vessels, disturbance of the 
  management of the metabolic cardiovascular load, and cardiac autonomic neuropathy. These 
  alterations make the diabetic heart susceptible to ischemia and less able to recover from an isch-
emic attack. Arterial hypertension frequently coexists with and exacerbates   cardiac functioning, 
leading to the premature appearance of heart failure. Classical and newer echocardiographic 
methods are available for early diagnosis. Currently, there is no specific treatment for DCM; 
targeting its pathophysiological substrate by effective risk management protects the myocardium 
from further damage and has a recognized primary role in its prevention. Its pathophysiological 
substrate is also the objective for the new therapies and alternative remedies.
Keywords: cardiovascular disease, atherosclerosis, cardiac autonomic neuropathy, 
  echocardiography, treatment strategies
Introduction
Cardiovascular disease is a common complication of diabetes responsible for 80% of 
the mortality in the diabetic population.1 Coronary artery disease is the leading cause 
for the increased cardiovascular morbidity and mortality in diabetes, and   atherosclerosis 
of the coronary vessels is its initial pathogenetic mechanism. Coronary artery disease 
and hypertension can account for most of the myocardial abnormalities (left   ventricular 
[LV] hypertrophy and impaired contractility) that occur in diabetes.   However, 
  postmortem, experimental, and observational studies also provide evidence for a 
specific cardiomyopathy in diabetes, which may contribute to myocardial   dysfunction 
in the absence of coronary artery atheroma.2 This is also sustained by the fact that 
patients with diabetes, independently of the severity of coronary artery disease, have 
increased risk of heart failure in comparison with subjects without diabetes.3,4
In 1972 for the first time in medical history, the description of 4 patients with 
diabetes and heart failure but without arterial hypertension or coronary artery disease 
appeared. The anatomical dissection of their hearts revealed LV hypertrophy and 
fibrosis without evidence of coronary artery atheroma or another substrate   pathology 
responsible for these findings. This clinical entity (disease) was considered as 
  independent and was baptized “diabetic cardiomyopathy” (DCM).5Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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The aim of this review is to provide up-to-date   information 
on the pathophysiology, diagnosis, and   management of DCM. 
We performed a comprehensive search in the PubMed and 
Embase databases up to February 2010 using the following 
keywords alone and in combination to retrieve available 
  literature data: “diabetes mellitus”, “  cardiomyopathy”, 
“  cardiac myocytes,” “  pathophysiology”, “hyperglyce-
mia”, “insulin resistance”, “risk factors”, “myocardial 
  performance”, “diastolic dysfunction”, “heart failure”, “diag-
nosis”, and “treatment”. All types of articles (randomized 
controlled trials, original studies, review   articles, and case 
reports) in humans and animals published in English language 
were included. Publications were studied in detail.
Epidemiological data on DCM
Epidemiological evidence has demonstrated worldwide 
that macrovascular complications (coronary artery disease, 
peripheral vascular disease, and stroke) are more common 
(2–4 times) among diabetes patients in comparison with the 
nondiabetes subjects. This is valid for both type 1 and type 
2 diabetes even when all other cardiovascular risk factors, 
such as hypertension, obesity, smoking, dyslipidemia, age, 
and sex, are taken into consideration.6
The Framingham Study showed that the frequency of 
coronary artery disease is twice more common in diabetes 
patients of both sexes, since women with diabetes appear 
to lose their normal premenopausal protection against 
  cardiovascular disease. Moreover, death from coronary artery 
disease is 3 times more common in diabetes patients com-
pared with nondiabetes subjects matched by age and sex. In 
other words, a patient with diabetes is not only at high risk 
of developing coronary artery disease, but furthermore, he is 
more susceptible to a worse prognosis.4 Atheromatous lesions 
have an earlier onset, faster development, and greater density 
in diabetes.7 The risk of coronary artery disease increases 
rapidly after the age of 40 in patients with type 1 diabetes, 
and by the age of 55, 35% of the patients of both sexes have 
died because of a coronary artery event, compared with 8% 
of men and 4% of women in the general population.8
It should be noted that in the last 30 years, the   substantial 
decrease in cardiovascular mortality in men without dia-
betes (up to 36.4%) was not followed by a decrease in the 
  cardiovascular mortality among the male diabetic population 
(up to 13.1% decline). Even more disappointing were the 
results among women. Although cardiovascular   mortality 
in women without diabetes was reduced by 17%, it was 
increased by 23% in the female diabetic population.9 This 
supports even further the loss of the premenopausal   protection 
against coronary artery disease in diabetes seen in healthy 
women. The STENO-2 Study demonstrated that in patients 
with type 2 diabetes, even when all associated cardiovascular 
risk factors are treated and the incidence of cardiovascular 
events is decreased by 50%, the   cardiovascular mortality 
still remains high.10
In one prospective study that included a population of 
1,059 patients with diabetes and 1,373 subjects without 
diabetes, who were followed up for at least 7 years, it was 
concluded that the frequency of mortality in patients with 
diabetes but without myocardial infarction was similar 
to that in subjects without diabetes but with myocardial 
infarction.11 Moreover, in patients with diabetes and acute 
myocardial infarction, mortality during the first month is 
above 42%, whereas in subjects without diabetes, it is less 
than 20%.12,13 Some studies have demonstrated that good 
glycemic control is associated with higher survival rates 
after acute myocardial infarction.14 In diabetes subjects 
with angiographically proven coronary artery disease, the 
survival rates are decreased by 30% compared with their 
nondiabetes counterparts.15 Diabetic nephropathy, which 
often coexists, especially proteinuria, increases further the 
risk of cardiovascular death.16 Moreover, a significant asso-
ciation between idiopathic cardiomyopathy and diabetes was 
recently described.17
An important consequence of DCM is heart failure, 
which is more common in people with diabetes and com-
plicates acute myocardial infarction more often than in the 
nondiabetic population. The increased percentage of patients 
with diabetes and heart failure in numerous multicenter 
epidemiological studies is in contrast to the total diabetic 
burden in the general population (6%–8%). In the Studies 
of Left Ventricular   Dysfunction (SOLVD), the percentage 
of patients with diabetes and heart failure was up to 26%,18 
whereas in the Assessment Trial of Lisinopril and Survival 
(ATLAS) study, it was 19%19 and in the Vasodilator-Heart 
Failure Trial II (V-HeFT II), it was up to 20%.20
These findings are in agreement for the presence of an 
additional detrimental factor in the diabetic myocardium, 
which predisposes it to extensive damage followed by heart 
failure. Even more, they are supportive for the early treatment 
of diabetes patients with aspirin and other   measures that are 
used for secondary prevention in the general   population, 
even in the absence of clinically apparent macrovascular 
complications.
In summary, cardiovascular disease is 2–3 times more 
common, and survival is worse in subjects with diabetes in 
comparison with age-matched and sex-matched counterparts. Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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The prevalence of heart failure with preservation of systolic 
function among patients with diabetes is 19%–26%.
Definition of DCM
DCM is defined as the cardiovascular damage present in 
diabetes patients, which is characterized by myocardial 
  dilatation and hypertrophy, as well as a decrease in the 
systolic and diastolic function of the left ventricle, and its 
presence is independent of the coexistence of ischemic heart 
disease or hypertension. DCM may be subclinical for a long 
time, before the appearance of clinical symptoms or signs. 
According to the molecular theory of DCM, hyperglycemia 
is the main pathogenetic factor, which causes abnormalities 
at the cardiac myocyte level, eventually leading to structural 
and functional abnormalities.21
The pathophysiological  
substrate of DCM
The anatomical damage  
of the myocardial substrate
Atheromatous plaques in patients with diabetes are not 
qualitatively different from those affecting the nondiabetic 
population. However, atheroma in patients with diabetes is 
more extensive, is more diffuse, and involves distal vessels 
in both the coronary and peripheral circulation.22 Pathologic 
anatomical alterations of the small coronary vessels and the 
myocardial endothelium include increased cell adhesiveness, 
impaired relaxation, impaired fibrinolysis, and increased 
permability.22 The early stages of DCM are dominated by 
the pathological alterations in the myocardial interstitium, ie, 
formation of nonenzymatic advanced glycation end products 
(AGEs), impaired compliance, and ischemia from the disease 
in the vasa vasorum. The morphology of the myocardial cells 
and small coronary vessels is anatomically preserved. These 
alterations lead to impaired myocardial contractility.23 As the 
disease progresses, LV hypertrophy appears as a result of 
the hypertrophy of the myocardial cells, the interstitial and 
perivascular fibrosis, the greater thickening of the capillary 
basement membrane, and the formation of microaneurysms 
in small capillary vessels. This ultimate observation may be 
the actual pathophysiological connection between diabetes 
microvascular and macrovascular disease.24
Structural alterations leading  
to ventricular dysfunction
Medial layers of arterioles throughout the cardiac circulation 
in diabetes show “hyaline” change, an amorphous, ground 
glass appearance, resulting from breakdown of structural 
proteins (largely thought to be collagen) and the uptake 
of glycated plasma proteins into the vessel wall. Similar 
changes are seen in older nondiabetes subjects as part of the 
aging process and in hypertension. The reduced blood   supply 
  resulting from microvascular disease and affecting the vasa 
vasorum in diabetes further   damages the small and medium 
arterioles of the diabetic heart. A clear relationship between 
the loss of cardiac function and the histological damage in 
the diabetic blood vessels is very difficult to   demonstrate. 
However, it is plausible that the structural changes and loss 
of elasticity   contribute to hypertension and possibly to the 
greatly increased risk of macrovascular events in diabetes. 
The European Heart   Association’s Guidelines (2009) have 
defined LV   hypertrophy as an increase in LV mass index 
above 125 g/m2 for men and above 110 g/m2 for women. The 
Framingham Study demonstrated that the   determination of 
LV hypertrophy   electrocardiographically was not   associated 
significantly with increased   cardiovascular morbidity and 
mortality.25 However, in the Framingham Study, when LV 
  hypertrophy was assessed echocardiographically in a popula-
tion of 3,222 patients, it was demonstrated that the relative 
risk for cardiovascular mortality for each 50 g/m2 increase 
of the LV mass above the normal limits was equal to 1.49 
for men and 1.57 for women.26
LV hypertrophy is significantly associated with an 
increase in markers of systemic inflammation, such as fibrino-
gen, C-reactive protein, and microalbuminuria. In one study 
including 1,299 patients with type 2 diabetes, microalbu-
minuria not only was a marker of endothelial dysfunction 
and increased risk of atherosclerosis but also was positively 
associated with LV mass.27
Functional alterations of DCM
Uncomplicated reduction of systolic myocardial functioning 
is defined as the loss of the heart’s ability to pump arterial 
blood in the peripheral circulation. However, the elementary 
difference between the uncomplicated reduction of systolic 
myocardial function and systolic heart failure is that in the 
latter, the clinical symptoms and signs of heart attack appear 
as a result of the former. Thus, the main guidance point of 
systolic myocardial dysfunction is the reduction of the LV 
ejection fraction.
However, recent studies revealed that the classical 
2-  dimensional echocardiography (2DE) may not be able 
to detect and diagnose the early uncomplicated   reduction 
of the LV systolic myocardial functioning. This is due 
to the fact that classical 2DE can determine only LV Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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  circumferential   function and cannot estimate LV longitudinal 
functioning.28
In DCM, progression and appearance of reduction of 
systolic function is slow, often when patients have already 
developed a significant reduction of diastolic myocardial 
functioning. The prognosis of patients with LV systolic 
myocardial dysfunction is poor, and the percentage of annual 
mortality is equal to 15%–20%.
Diastole is defined as the period when the myocardial 
muscle generates effort and energy, while in mechani-
cal (  isovolumic deceleration and relaxation phase) and 
  electrophysiological inactivity (automatic depolarization).29 
Reduction of diastolic myocardial functioning is determined 
by a delayed and extended diastolic phase. Diastolic dys-
function is also characterized electrophysiologically by the 
prolongation of the active dilatation and the augmented pas-
sive stiffness of the left ventricle, which portray the   passive 
diastolic LV compliance in heart failure.30 Impaired diastolic 
functioning of the left ventricle appears in 27%–69% of the 
cardiovascular asymptomatic population with diabetes31 and 
is responsible for the 30% of the patients ending up with 
diabetes and clinical symptomatic heart failure.32 Impaired 
diastolic compliance and maintenance of the systolic function 
is usually the initial heart lesion in the   progression of DCM.33 
Failure of diastolic relaxation of the left ventricle leads to 
impaired filling and reduced cardiac reserve on exercise. 
In spite of the absence of systolic dysfunction, numerous 
clinical studies have demonstrated a decreased ejection 
fraction, which determines reduced cardiac residual reserve 
in asymptomatic patients with diabetes.34 Subclinical DCM 
characterized by reduced cardiac residual reserve can develop 
into a significant clinical entity, especially when myocardial 
ischemia coexists or suddenly appears.
Diastolic myocardial function can be evaluated by cardiac 
catheterization for the evaluation of the isovolumic   relaxation 
rhythm and the LV isovolumic contraction time.35 This 
method, although highly accurate, for the evaluation of LV 
diastolic function is invasive and has increased possibilities 
of accidental injury. The alternative noninvasive techniques 
include classical 2DE and M-mode echocardiography with 
Doppler. LV diastolic functioning can also be evaluated by 
controlling the transmitral and pneumocardial blood flow.36
The medical term “diastolic dysfunction” refers exclu-
sively to the echocardiographic finding of an abnormal LV 
deceleration and relaxation time, without the coexistence of 
any clinical evidence suggestive of heart failure. However, 
diastolic heart failure is defined as the clinical syndrome 
of heart failure with preservation of a normal LV ejection 
fraction. Echocardiographic findings of isolated myocardial 
dysfunction, such as subclinical reduction of myocardial 
diastolic compliance and loading, are reliable prognostic 
markers of future chronic heart failure.37 Moreover, patients 
with diastolic heart failure have increased cardiovascular 
mortality (equal to 5%–8%) compared with healthy subjects 
matched by age and sex (equal to 1%).38–40
The impact of diastolic dysfunction is associated 
with good glycemic control, as assessed by hemoglobin 
A1c (HbA1c) levels.41 Possibly, the main cause for this 
  relationship are the increased circulatory AGEs42 and the 
increased   production of free oxygen radicals,43 resulting in 
an increased accumulation of collagen in the myocardium 
and in   myocardial fibrosis.44,45
Coexistent hypertension accelerates the functional under-
lying process, leading to LV hypertrophy, systolic ventricular 
dysfunction, and greatly increased risk of congestive heart 
failure. Although, it is difficult to disentangle the effects of 
hypertension from the other facets of the pathophysiology of 
ventricular dysfunction in diabetes, LV hypertrophy has also 
been observed in nonhypertensive individuals with diabetes, 
and particularly in women.46
In conclusion, DCM is characterized by LV hypertrophy 
and myocardial dilatation, which lead to LV diastolic and 
systolic dysfunction. These are related to diabetic fibrosis, 
inflammation, ischemia, and presence of microvascular 
complications. DCM is independent of the coexistence of 
ischemic heart disease or hypertension.
The molecular substrate of DCM
Hyperglycemia causes significant functional alterations to 
the cellular Na+–Ca2+ ionic channel, resulting in a decreased 
extrapolation and an increased intracellular concentration 
of ionic calcium. Moreover, in diabetes, a dysfunction of 
the cellular Na+–K+ ionic channel appears, which primarily 
causes an increase in the intracellular sodium concentration 
and secondarily an additional increase to the already aug-
mented intracellular calcium concentration in the diabetic 
cardiac myocytes.47
Dyslipidemia and increased production of free oxygen 
radicals48,49 may cause metabolic alterations to the genetic 
transcription factors and coding.50,51 The result of these altera-
tions is a modification in the translation of   nucleoprotein 
genes, such as RAS and insulin-like growth factor 1 (IGF-1), 
responsible for the myocardial substrate and myocardial fiber 
structure and also for the maintenance of a normal   myocardial 
compliance.52,53 Accordingly, increased expression of the 
early cardiopathology-related gene RAS predisposes to Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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insulin resistance, whereas the IGF-1 increases   myocardial 
contractility through an increase of the   intracellular   calcium 
accumulation and by intensifying the sensitivity of the 
  cardiac myofibers to the circulatory calcium concentra-
tion.54 IGF-1 is present in the cardiac myocytes, and its 
expression is augmented by decreased insulin concentra-
tion, increased mechanical stress, and increased peripheral 
vascular resistance. IGF-1 acts synergically with angiotensin 
II in   promoting cellular development. As a result, this leads 
to myocardial hypertrophy of the diabetic heart ventricle 
mass even when blood pressure levels are within the normal 
range.55
Thus, hyperglycemia, dyslipidemia, and increased 
  production of free oxidant radicals are main metabolic 
pathogenetic risk factors leading to DCM.
The interplay of cardiac autonomic 
neuropathy in DCM
Cardiac autonomic neuropathy (CAN) is a common compli-
cation of diabetes, causing abnormalities in heart rate control 
and in central and peripheral vascular dynamics. CAN affects 
almost 17% of the patients with type 1 and 22% of those with 
type 2 diabetes. An additional 9% of patients with type 1 
and 12% of those with type 2 diabetes have milder forms of 
autonomic dysfunction.56
Several studies have confirmed that cardiac   neuropathy 
has the propensity to cause a reduction in the cardiac 
  ejection fraction, impair systolic dysfunction and decrease 
diastolic filling, thus having an important contribution 
to the   deterioration of diastolic myocardial function and 
DCM. Abnormalities of LV diastolic filling are overstated 
in patients with diabetes and CAN in comparison with 
patients with diabetes but without this complication.57 
When LV   function was assessed in a diabetic population 
by resting and exercise radionuclide ventriculography, an 
abnormal LV performance was revealed in 37% of the 
patients included in the study. CAN was present in 59% of 
the subjects with DCM, a significantly increased incidence 
compared with that of 8% in the patients without this com-
plication. Moreover, there were significant reductions in 
the ventricular ejection   fraction at rest and with maximal 
exercise in patients with CAN   compared with those without 
this complication.58
In a population of subjects with type 1 (insulin-dependent) 
diabetes, a decrease of the diastolic myocardial function to 
21% was also demonstrated. None of the patients included 
in the study had clinical evidence of coronary artery disease, 
and diastolic myocardial dysfunction (impaired diastolic 
LV filling) was significantly associated with the presence 
of CAN.59
CAN is portrayed by a significant reduction in heart rate 
variability and an alteration in the parasympathetic– sympathetic 
balance, in which a reduction in parasympathetic tone sec-
ondary to autonomic neuropathy leads to a relative overac-
tivity of the sympathetic system. Patients with diabetes and 
mild CAN have been shown to have distal LV sympathetic 
denervation, whereas patients with severe CAN have a pattern 
of distal sympathetic denervation associated with proximal 
ventricular islands of hyperinnervation. These areas of den-
ervation and hyperinnervation may cause unstable regions 
of electrical, vascular, or autonomic heterogeneity conducive 
to DCM.60
Numerous studies have demonstrated a significant cor-
relation between dysfunction of the parasympathetic nervous 
system activity and impaired myocardial function. One study 
evaluated the role of parasympathetic nervous system activity 
in cardiovascular performance on a group of clinically asymp-
tomatic type 2 diabetes patients, ie, without any symptom, 
sign, or objective measurement of ischemia or cardiomyo-
pathy. Although patients with CAN   corresponded positively 
to the increase in oxygen uptake by an   equivalent percent 
increase in cardiac output, this response was   significantly 
reduced compared with that of patients without CAN. Thus, 
it was shown that impaired sympathetic and parasympathetic 
responses, which normally augment cardiac output and redi-
rect peripheral blood flow to skeletal muscles during exertion, 
may limit exercise tolerance.61
The relationship between parasympathetic nervous 
  dysfunction and DCM was confirmed by an important decrease 
of heart rate variability during deep breathing maneuver in sub-
jects with type 1 diabetes and by the   presence of pathological 
echocardiographic findings of the LV filling rhythm.62
Dysfunction of the sympathetic nervous system activity 
has been associated with a decrease in both systolic and dia-
stolic myocardial function in subjects with type 2 diabetes.63 
A significant association between a decrease of the transmi-
tral ratio of early to late peak mitral filling wave velocities 
and the augmentation of sympathetic myocardial neurosis 
has also been demonstrated.64 This relationship has confirmed 
that in DCM, the abnormal cardiac sympathetic neurosis 
contributes to the abnormal LV filling. The transmitral ratio 
of early to late peak mitral filling has also been associated 
with orthostatic hypotension as a clinical manifestation of 
CAN.46 Moreover, the same index of abnormal cardiac filling 
was associated with an abnormal expiration/inspiration ratio, 
ie, an index of parasympathetic dysfunction in patients with Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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type 1 diabetes and CAN.65 Finally, CAN is associated with 
a decrease of the elastic vascular properties and an increase 
of peripheral vascular resistance due to the augmentation of 
the sympathetic nervous tone.66
Resting tachycardia reduces the heart’s ability to pump 
blood in the peripheral circulation and interferes with the 
  ventricular chambers’ capacity to fill with blood   properly. 
Ventricular tachycardia not only reduces the time of ven-
tricular filling but also interferes with the timely atrial con-
traction. When the heart’s labor capacity is greatly reduced 
for a prolonged period, cardiac arrest and death are likely to 
happen.67 Through predisposition to arrhythmias, CAN may 
lead to LV dysfunction followed by sudden death.68 Recent 
studies revealed that classical69,70 and newer markers of 
arrhythmogenicity71 are increased in subjects with diabetes 
and CAN in comparison with subjects with diabetes but with-
out this complication. Moreover, one recent study revealed 
that increased markers of spatial ventricular heterogeneity 
in type 2 diabetes subjects and CAN are associated with the 
structural and functional properties of the myocardium.71
In conclusion, CAN is strongly and independently associ-
ated with the structural and functional pathogenetic substrate 
of DCM in both type 1 and type 2 diabetes patients. This 
is partially explained by the significant reduction in heart 
rate variability present in autonomic neuropathy, and an 
alteration in the parasympathetic–sympathetic balance of the 
heart, leading to parasympathetic reduction and sympathetic 
overactivity.
Risk factors for DCM
Hyperglycemia
Hyperglycemia could contribute to macrovascular   disease 
through various mechanisms. Hyperglycemia causes 
  significant functional alterations to the cellular Na+–Ca2+ 
ionic channel, resulting in a decreased extrapolation and an 
increased intracellular concentration of ionic calcium. More-
over, in diabetes, a dysfunction of the cellular Na+–K+ ionic 
channel appears, which primarily causes an increase in the 
intracellular sodium concentration and secondarily an addi-
tional increase to the already augmented intracellular calcium 
concentration in the diabetic cardiac myocytes.47 However, 
the most convincing pathogenetic mechanism of hypergly-
cemia is via the formation of AGEs. AGEs cross-link vessel 
wall proteins, therefore causing thickening and leakage of the 
vasculature and forming irreversible and abnormal deposits 
of plasma-derived proteins in the myocardial subintimal 
arterial layers.72 Furthermore, AGEs generate toxic reactive 
oxygen species (ROSs) that impair cellular interactions and 
damage myocardial vascular function, causing endothelial 
vasomotor dysfunction.73
Some of the effects of AGEs are mediated through spe-
cific receptors (RAGE) expressed by vascular endothelial, 
smooth muscle cells and cardiac myocytes. In the cardiac 
endothelium, AGE–RAGE interaction leads to   upregulation 
of procoagulant and adhesive proteins, including tissue 
factor, plasminogen activator inhibitor 1 (PAI-1), and 
  vascular cell adhesion molecule 1 (VCAM-1). Expression of 
VCAM-1 results in an increase in monocyte adhesion, while 
monocytes expressing RAGE are recruited by   chemotaxis 
to sites of AGE accumulation. There they infiltrate the 
  myocardial subendothelium to form foam cells, an early step 
in atherogenesis. Other extracellular RAGE ligands are the 
  RAGE-binding proteins that interact with RAGE on cardiac 
myocytes to induce expression of tumor necrosis factor α 
(TNF-α), VCAM-1, nuclear factor κB (NF-κB), and inter-
leukin 1, thus modulating the inflammatory component of 
cardiovascular disease through the cytokine cascade.74
A strong relationship between glycemic control and DCM 
has been demonstrated in major multicenter   prospective 
studies. The Diabetes Conventional and Complications 
Trial (DCCT) showed that patients with diabetes who are 
conventionally treated have a nearly double incidence of 
DCM when compared with patients with diabetes who 
are intensively treated. Among the risks for DCM, beyond 
  glycemic control, were increased levels of serum   cholesterol 
and triglycerides.75 For each 1% reduction in HbA1c, the 
United Kingdom Prospective Diabetes Study (UKPDS) 
demonstrated a 14% reduction in myocardial infarction.76 
Moreover, impaired glucose tolerance has been identified 
as a risk factor for DCM, suggesting that even mild hyper-
glycemia may contribute to DCM.77
insulin resistance and the metabolic 
syndrome
Insulin resistance and hyperinsulinemia have been   identified 
as risk factors for DCM.78,79 In hyperinsulinemia and   insulin 
resistance, an imbalance in the direct effects of insulin 
action occurs, accompanied by the confounding effects of 
other cardiovascular risk factors associated with the insulin 
resistance syndrome, ie, central obesity, hyperglycemia, 
hypertriglyceridemia, low high-density lipoprotein (HDL), 
and hypertension.80 The clustering of these cardiovascular 
and atherothrombotic risk factors that accompany   insulin 
resistance provides a plausible basis for DCM and is 
often associated with adverse cardiovascular effects.81,82 
  Hyperinsulinemia and insulin resistance are also associated Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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with a cluster of thrombotic risk factors, such as elevated 
levels of PAI-1,83,84 factor VII, factor XII, and fibrinogen.85–87 
Increased levels of factor VII and XII may also occur through 
activation by triglyceride-rich particles, whereas hyperfi-
brinogenemia may be attributed to smoking, increased body 
mass, and inflammatory responses.
Insulin resistance is often associated with a combina-
tion of established and emerging risk factors, including 
hypertension and C-reactive protein.88,89 C-reactive protein 
is an acute-phase inflammation marker that has been asso-
ciated with an increased risk for DCM.90,91 Recent studies 
have confirmed the association between increased levels of 
C-reactive protein and worse LV myocardial performance, 
as well as risk factors for atherosclerosis and cardiovascular 
disease in subjects with metabolic syndrome (MetS).92 MetS 
status per se was found to be the strongest predictor of cardio-
myopathy, thus implying that the clustering of the metabolic 
disturbances has additional prognostic information than its 
individual components in terms of myocardial performance 
and may explain in part the excess cardiovascular risk pres-
ent in the MetS.92
In conclusion, the effects of insulin on the diabetic heart 
are related to both systemic metabolic abnormalities and the 
direct effects of insulin action on the vasculature. Although, 
the elevation and the imbalance of the cardiovascular and 
atherothrombotic metabolites and cytokines related to hyper-
insulinemia and insulin resistance have a crucial contribution 
in the pathogenesis of DCM, it should be noted that the direct 
action of insulin on the vasculature has also been proposed to 
mediate a combination of proatherogenic and antiatherogenic 
effects related to endothelial function and smooth muscle cell 
growth.93 The importance of insulin resistance and the MetS 
is further confirmed by the fact that insulin-resistant individu-
als who are either hyperinsulinemic and normoglycemic79 or 
hyperinsulinemic with impaired glucose tolerance94 show 
a similarly high-risk profile to those with overt diabetes, 
whereas others who are destined to develop diabetes, but lack 
insulin resistance, are not at increased risk.81,95
Dyslipidemia
Increased atherogenesis and insulin resistance in diabetes 
and MetS have been attributed in large part to a proathero-
thrombotic dyslipidemia, related to hypertriglyceridemia, 
elevated very low-density lipoprotein, and decreased HDL 
cholesterol levels.96,97 Insulin resistance results in increased 
levels of triglyceride-enriched, small, dense low-density 
lipoprotein (LDL) particles, which have been associated 
with an increased risk of ischemic heart disease.98   Moreover, 
the combined elevation of fasting insulin, apoprotein B, 
and small, dense LDL particles has been identified as a 
  nontraditional risk factor cluster for coronary artery   disease.99 
Dyslipidemia has been recently associated with worse 
myocardial performance in type 2 diabetes subjects100 and 
in the MetS.92 Additional risk factors for DCM associated 
with dyslipidemia include increased lipoprotein(a)101 and 
nonesterified fatty acids.102
Hypertension
Hypertension commonly coexists with type 1 and type 2 
diabetes. Hypertension per se is a major risk factor for vas-
cular complications, ie, myocardial infarction and stroke.103,104 
According to major multicenter studies, the majority (almost 
50%) of patients with diabetes and no clinical evidence of 
atheromatous disease are hypertensive or are taking antihy-
pertensive drugs. In diabetes subjects with DCM, the preva-
lence of hypertension is even higher.105 Insulin resistance has 
been proposed to be the fundamental cause of hypertension 
and DCM in type 2 diabetes.106 Acquired factors such as obe-
sity and physical inactivity may also contribute. Hypertension 
is an important feature of the cluster of the cardiovascular 
risk factors included in the MetS. The relationship between 
these metabolic components is complex and in part largely 
unexplained. Insulin resistance could raise blood pressure 
by the loss of insulin’s normal vasodilator activity,107 or 
through effects of the accompanying hyperinsulinemia. 
These include Na+ and water retention, increased intracel-
lular Na+ concentrations108 that enhance the contractility and 
stimulate proliferation of vascular smooth muscle,109 increase 
peripheral resistance, and cause sympathetic overactivity.110 
In other words, hypertension and DCM are synergic and 
share similar pathogenetic pathways. The characteristic 
dyslipidemia of insulin resistance that contributes to DCM 
may also contribute to hypertension, as small, dense LDL 
particles are especially susceptible to oxidation, and oxidized 
LDL can suppress endothelial nitric oxide production and so 
promote vasoconstriction; hypertriglyceridemia also impairs 
endothelium-dependent vasorelaxation.111 Studies have 
shown that fibrates used to treat hypercholesterolemia also 
reduce the prevalence of hypertension up to 25%.112
Obesity
Obesity predisposes to type 2 diabetes, hypertension, dyslipi-
demia, and ultimately atheroma, which is one of the major 
causes of premature death in obese people.113 Obesity is 
recognized as an independent cardiovascular risk factor.114 
Central obesity is characterized by excess fat deposited Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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both subcutaneously around the abdomen and within the 
visceral cavity and is commonly found in patients with type 2 
  diabetes and MetS. Central obesity is associated with insulin 
resistance and proinflammatory responses that cause glucose 
intolerance and a highly atherogenic-risk profile. Adipose 
tissue produces nonesterified fatty acids and cytokines such 
as TNF-α that may contribute to both insulin resistance and 
atherogenesis. Reduced levels of adiponectin, an insulin-
sensitizing protein whose secretion by adipose tissue is para-
doxically decreased in obesity, may also contribute to insulin 
resistance and DCM.115 Indeed, in a recent study, central obe-
sity, as part of the MetS, was significantly and independently 
associated with LV myocardial dysfunction.116
The effect of diabetic nephropathy
Nephropathy is a common complication affecting almost 
one-third of patients with diabetes.117 Both microalbuminuria 
(albumin excretion rate of 30–299 mg/24 h) and proteinuria 
(albumin excretion, .300 mg/24 h) are markers of increased 
cardiovascular risk.118,119 In type 1 diabetes, the relative risk 
of DCM is 1.2-fold in patients with microalbuminuria120 and 
10-fold in patients with proteinuria121 compared with patients 
with normoalbuminuria. In type 2 diabetes, the risk of DCM 
is increased 2- to 3-fold in microalbuminuria122 and 9-fold 
in proteinuria.123
The onset of microalbuminuria is associated with an 
excess of cardiovascular risk factors, including hyperg-
lycemia, dyslipidemia, and numerous prothrombotic and 
atherogenic changes.124,125 Moreover, there is growing evi-
dence that the genetic susceptibility influences the develop-
ment of diabetic nephropathy and also affects the diabetic 
  cardiovascular system.126 Suggested mechanisms linking 
renal and cardiovascular disease include endothelial dys-
function, abnormalities of the renin–angiotensin system, and 
widespread vascular basement membrane defects.
In conclusion, the pathogenic contribution to the devel-
opment of DCM includes insulin resistance, increased 
formation of AGEs, MetS, hyperglycemia, dyslipidemia, 
obesity, and presence of microangiopathy. Their interplay 
is complex, since they can act in parallel and synergically 
and, at the same time, have a cause and effect result. Thus, 
they should be equally predicted and effectively treated. 
The   contribution of the various factors in the development 
of DCM is depicted in Figure 1.
The diagnostic paths through DCM
Echocardiography is a reliable, noninvasive technique for the 
determination of LV hypertrophy and the reduction of both 
systolic and diastolic myocardial function. Moreover, it has 
a prognostic value for the early diagnosis of DCM.
The classical echocardiographic markers 
of DCM: advantages and disadvantages
Early deteriorations of myocardial function are characterized 
by a normal ejection fraction and a decrease in ventricle 
filling during the initial phase of diastole. Prolongation of 
isovolumic myocardial relaxation and an increase in atrial 
filling further confirm a decrease in diastolic myocardial 
function. The Framingham study showed an increase of 
LV mass in women with diabetes, independent of the 
effects of other traditional risk factors.46 Subsequent   studies 
confirmed these results in both genders, highlighting 
  associations of both diabetes and glucose intolerance with 
LV structure   abnormalities, independent of the influence of 
relevant   covariates, such as arterial blood pressure levels 
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Figure 1 The pathophysiological substrate of diabetic cardiomyopathy: in diabetes, 
hyperglycemia, excess free fatty acid (FFA) release, and insulin resistance, engender 
adverse  metabolic  events  that  affect  the  cardiac  myocytes.  Hyperglycemia  is 
associated with decreased glucose transportation (GLUT), uptake, and oxidation, 
as well as increased formation of advanced glycation end products (AGes) and 
increased activation of protein kinase C (PKC). excess FFA release is followed by 
cardiac lipotoxicity, ie, increased cardiac lipid accumulation and increased generation 
of reduced reactive oxygen species (ROS) at the level of the electron transport 
chain. Together with insulin resistance and impaired insulin action and signaling, 
these metabolic paths augment vasoconstriction, produce and further aggravate 
arterial hypertension, increase inflammation with liberation of leukocyte-attracting 
chemokines, increase production of inflammatory cytokines, and augment expression 
of  cellular  adhesion  molecules.  Thrombosis  is  further  promoted,  together  with 
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and treatment with angiotensin-converting enzyme (ACE) 
inhibitors.43,127–130 The same was true for patients with type 1 
diabetes.131 Early echocardiographic studies revealed that 
half of the diabetic population with decreased myocardial 
diastolic function remain undiagnosed with the classical 
echocardiographic techniques. This is due to the fact that the 
echocardiographic subestimation of the degree of diastolic 
dysfunction with the classical echocardiographic markers 
in the subjects with normal arterial blood pressure levels is 
equal to 60%.132,133
The newest echocardiographic markers: 
their performance structure and role  
as diagnostic tools
Total ejection isovolumic (TEI) index is a myocardial per-
formance index and a method for the global estimation of 
the LV performance.134 The TEI index is not influenced by 
the increased left atrial loading pressure often present in the 
advanced stages of diastolic heart failure, which is a key 
advantage compared with the classical echocardiographic 
methods.135,136 The isolated estimation of the decrease in 
diastolic myocardial function has been recently questioned 
owing to the presence of reduced systolic function in patients 
with normal ejection fraction. Therefore, evaluation of TEI 
index may become a valuable tool for the early diagnosis of 
upcoming myocardial ischemia.137
An important limitation of the single use of TEI index 
for the estimation of myocardial dysfunction is that it does 
not allow the evaluation of the pathogenetic substrate of 
myocardial dysfunction because it cannot evaluate the 
myocardial pressure levels during diastolic filling or the 
changes in systolic preload.138 However, the clinical signifi-
cance of TEI index as a diagnostic tool for New York Heart 
Association Grade I–III heart failure was recently success-
fully demonstrated and was identical when compared with 
the results of invasive techniques.139 Moreover, TEI index 
was demonstrated as a significant prognostic marker of 
cardiovascular morbidity and mortality in elderly patients, 
independent of the coexistence of the classical cardiovascular 
risk factors.140
In a recent study in type 2 diabetes patients without 
  macrovascular complications, TEI index was significantly and 
independently associated with the presence of DCM.100 More-
over, in type 2 diabetes patients with DCM, higher values 
of the TEI index were associated with increased   ventricular 
arrhythmogenicity, suggesting a significant   association 
between the underlying LV diastolic   dysfunction and the 
LV electrophysiological activity of the diabetic heart. This 
  association was further supported by the   findings of another 
study in a nondiabetic population with MetS, where worse 
myocardial function, assessed by higher TEI index   values, 
was associated with increased ventricular   arrhythmogenicity.92 
This study concluded that the electrophysiological abnormali-
ties present in the MetS may be due to the direct effects of 
hyperinsulinemia on myocardial membrane activity or the 
electrophysiological alterations that accompany the bio-
chemical and functional abnormalities caused by the shift 
in the myocardial substrate utilization.141
MetS was also associated with worse myocardial per-
formance assessed by the TEI index in a population without 
diabetes, hypertension, or other macrovascular complications. 
This association was confirmed for the MetS per se, the sum 
of its components and its particular components. Additionally, 
it was demonstrated that factors associated with conditions 
commonly associated with MetS, such as insulin resistance, 
low-grade inflammation, and microalbuminuria, were also 
associated with worse LV myocardial performance.116
Other modern echocardiographic techniques, such as 
transmitral pulsed Doppler and its applications (strain and 
strain rate), which are less susceptible to the alterations of 
the cardiac loading conditions, have recently demonstrated 
63% sensitivity against the 50% of the pulsed Doppler in 
diagnosing DCM.137,142–144 Table 1 shows the main echocar-
diographic findings and the incidence of DCM in major and 
recent studies.
Treatment strategies of DCM: risk 
factors, management and lessons 
from studies
Lifestyle
Regular physical exercise and limitation of fat and total 
energy intake remain the cornerstone of the management 
of overweight diabetes patients who currently represent 
80% of type 2 and at least 25% of type 1 diabetes patients 
worldwide. Patients with diabetes should be encouraged 
to undertake moderate aerobic activity, ie, walking for 
30–45 min everyday. Patients with angina or breathlessness 
on exertion should exercise within their limitations, aiming 
gradually to increase their activity. In obese patients with a 
body mass index (BMI) . 30 kg/m2, an initial target should 
be 10% weight loss; in those who are not obese, a target BMI 
of #25 kg/m2 may be reasonable.
One prospective, randomized, controlled study   evaluated 
the effects of diet and exercise on the reduction of the   overall 
incidence of DCM in patients with type 2 diabetes for a 
follow-up period of 6 years. Subjects were randomized either Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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to a control group or to 1 of the 3 active treatment groups, ie, 
diet only, exercise only, or diet plus exercise. The   cumulative 
incidence of DCM at 6 years was 67.7% in the control group 
compared with 43.85% in the diet group, 41.1% in the exer-
cise group, and 46% in the diet plus exercise group. Each of 
the active intervention groups differed significantly from the 
control group (P , 0.05). In a proportional hazards analysis 
comparing the 3 intervention groups to the control group, there 
was a reduction in the cardiovascular risk of 33% in the diet 
group (P , 0.03), 47% in the   exercise group (P , 0.0005), 
and 38% in the diet plus exercise group (P , 0.005). In con-
clusion, lifestyle changes with diet and/or exercise interven-
tions led to a significant decrease in the incidence of DCM 
over a 6-year period among subjects with type 2 diabetes.145
Another randomized, blinded study with a mean 
  duration of 3.2 years evaluated the feasibility and effects of 
a   program of lifestyle changes designed to prevent or delay 
the onset of type 2 diabetes in 523 middle-aged, overweight 
(BMI ∼31.3 kg/m2) subjects with impaired glucose tolerance 
and the incidence of DCM in patients with type 2   diabetes.146 
The intervention group consisted of individualized counsel-
ing aimed at reducing weight and total fat intake and increas-
ing fiber intake and physical activity (at least 30 min per day). 
During the trial, the risk of diabetes was reduced by 58% 
in the intervention group and was directly   associated with 
changes in lifestyle. The changes in lifestyle also reduced 
(by 56% in both men and women) the magnitude of DCM 
incidence.147
Cigarette smoking is an obvious and important   modifiable 
risk factor for cardiovascular disease. Smoking cessation 
confers immediate and lasting benefits that are likely to 
be even greater in people with diabetes, whose vascular 
risk is further increased by smoking. In the Multiple Risk 
Factor   Intervention Study (MRFIT), the absolute risk of 
  cardiovascular death over 12 years was much higher for 
diabetes subjects compared with the nondiabetes participants 
Table 1 Main and recent echocardiographic, population-based studies on diabetic cardiomyopathy
Reference Population sample Findings Incidence of DCM
[46] 1,986 men + 2,529 women  
(111 with DM + 381 with iGT)
↑ LV wall thickness, ↑ relative wall thickness,  
↑ LV end-diastolic dimension, ↑ LV mass
13.9% in men  
16.1% in women
[127] 5,201 men + women  
(2,697 with DM or iGT,  
age $ 65 years)
↑ ventricular septal thickness, ↑ posterior wall  
thickness, ↑ left ventricular mass, ↑ early and late  
diastolic transmitral peak flow velocities
40% in both sexes
[43] 1.810 men + women with DM ↑ LV mass, ↑ LV wall thicknesses ↓ LV fractional  
shortening, ↓ midwall shortening,  
↓ stress-corrected midwall shortening
14% in women  
12% in men
[128] 1,950 men + women with HTN  
(386 with DM)
↑ LV mass, ↑ LV relative wall thickness, concentric LV  
geometry, ↓ LV stress-corrected midwall shortening,  
↓myocardial function (↓ midwall and ↓ stress-corrected  
midwall fractional shortening)
38% in both sexes
[129] 3,628 men + women  
(457 men + women with iGT)
↑ LV mass, ↑ cardiac index, ↑ LV wall thicknesses and  
↑ relative wall thickness
12.6% in both sexes
[130] 173 men + women with DM + HTN ↑ LV mass 30% in both sexes
[131] 39 boys + girls with type 1 DM ↑ LV mass, ↓ LV performance 30% in both sexes
[100] 148 men + women (74 with DM) ↑ LV mass index, ↑ Tei index 34% in both sexes
[92] 306 men + women  
(153 with MetS)
↑ LV mass index, ↑ Tei index 12% in both sexes
[116] 550 men + women  
(275 with MetS)
↑ Tei index 18% in both sexes
[142] 186 type 2 diabetes patients  
with normal ejection fraction
Systolic dysfunction: ↓ peak strain and ↓ strain rate  
↑ calibrated IB (myocardial reflectivity)
15.8% in both sexes
[143] 41 diabetes patients with normal  
resting LV function and a normal  
dobutamine echo
↓ peak myocardial systolic velocity  
↓ early diastolic velocity
16% subtle dysfunction   
in both sexes
[137] 35 type 2 diabetes patients ↓ longitudinal peak systolic velocity at rest and at  
peak stress, ↓ functional reserve, ↑ radial systolic velocity
20% in both sexes
[144] 134 type 2 diabetes patients ↓ mean peak systolic early + diastolic  
velocity, ↓ mean isovolumic relaxation time,  
↑ systolic + diastolic synchronicity
20% in both sexes
Abbreviations: DCM, diabetic cardiomyopathy; DM, diabetes mellitus; iGT, impaired glucose tolerance; LV, left ventricular; HTN, hypertension; Tei, total ejection 
isovolumic; MetS, metabolic syndrome; iB, integrated backscatter.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
893
Diabetic cardiomyopathy: an insight review
and was significantly associated with reported number of 
cigarettes/day (P , 0.0001). Together with dyslipidemia and 
hypertension, cigarette smoking was a dominant predictor of 
cardiovascular morbidity (increased risk for DCM by 53% 
in both sexes) and cardiovascular mortality (overall 3 times 
higher risk of death from heart failure).103,148
Optimizing glycemic control
This is an important treatment aim in the management of 
DCM. A prospective cohort study analyzed the relative risk 
of macrovascular disease in patients with newly diagnosed 
type 2 diabetes and determined whether an intensive approach 
to dietary management, besides satisfactory glycemic con-
trol, would ameliorate the long-term cardiovascular risk and 
reduce the incidence of DCM and cardiovascular mortality. 
The study compared dietary management alone to oral 
hypoglycemic therapy (tolbutamide 500 mg or metformin 
twice a day) with continued diet and finally insulin regimen. 
At the end of the 10-year follow-up period, the survival rate 
was 75%, whereas 26% of the patients suffered myocardial 
infarction, of which 41% was fatal. The analysis of baseline 
data showed a relative risk equal to 1.04 for myocardial 
infarction for each 1 mmol/L increase in fasting plasma 
glucose. The risk of myocardial infarction while on insulin 
or oral treatment was not significantly elevated relative to 
dietary treatment. The study concluded that fasting plasma 
glucose is a significantly independent predictor of diabetic 
macrovascular disease, and the type of antidiabetic treatment 
does not prevent long-term cardiovascular disease.149
The epidemiological analysis of a prospective, multicenter, 
population-based study of patients with newly diagnosed type 2 
diabetes demonstrated that the incidence of myocardial infarc-
tion was 15.2% and of these 19.2% died. The results showed 
that good glycemic control was associated with lower risk 
not only for myocardial infarction (15.2% vs 42%) but also 
for DCM (15% vs 32%). Good glycemic control was associ-
ated with a lower incidence of DCM (27% vs 9%), whereas 
postprandial blood glucose levels were among the independent 
predictors for cardiovascular morbidity and mortality.150,151 
The UKPDS evaluated the relationship between exposure to 
glycemia over time and the development of DCM in patients 
with type 2 diabetes. For each 1% reduction in mean HbA1c, 
there was a 14% associated decrease in risk for myocardial 
infarction and a 16% decrease in risk for heart failure.152
Management of dyslipidemia
A double-blind, randomized, placebo-controlled, multicenter 
clinical trial assessed the effect of cholesterol lowering with 
simvastatin on mortality and the risk of coronary heart 
  disease in patients with diabetes and DCM. Treatment of 
dyslipidemia significantly decreased the risk of coronary heart 
disease (recurrent myocardial infarction) by 55% (P = 0.002) 
in subjects with type 2 diabetes. Since in diabetes subjects 
with DCM the case fatality is very high, aggressive lipid 
lowering should be extended to diabetes subjects who have 
not yet experienced a clinical event (primary and secondary 
prevention).153
Another multicenter, randomized, double-blind, placebo-
controlled study determined if treatment with gemfibrozil 
would reduce the incidence of major cardiovascular events 
and outcomes in patients with type 2 diabetes. DCM was 
reduced by 22% with gemfibrozil treatment, and major 
cardiovascular events were reduced by 24%. For every 
5 mg/dL increase in HDL cholesterol, there was an 11% 
reduction in cardiovascular events.154 The effect of lipid-
lowering treatment at various levels of glucose tolerance 
or hyperinsulinemia was also evaluated by the same group, 
and the association between diabetes status, glucose–insulin 
levels and cardiovascular risk was examined. In patients 
with diabetes, a fasting plasma insulin level $ 271 pmol/L 
was associated with a 31% increased risk of cardiovascular 
events. Gemfibrozil was effective in patients with diabetes, 
and the reduction in DCM was 53%, whereas in cardiovas-
cular mortality, it was 41%.155–157
Hypertension management  
and renoprotection
A randomized, double-blind, active-controlled clinical 
trial reached to determine whether the combined incidence 
of fatal coronary heart disease and nonfatal myocardial 
  infarction   differs between diuretic treatment (  chlorthalidone) 
and 3 alternative therapies: calcium channel blockers 
(amlodipine), ACE inhibitors (lisinopril), and α-blockers 
(doxazosin). The incidence of DCM was higher in the group 
under therapy with α-blockers compared with diuretics 
(relative risk equal to 1.25 at a 4-year rate). No significant 
differences were observed between calcium channel   blockers, 
ACE inhibitors, and diuretics for the primary outcome or 
for all-cause mortality. Amlodipine had a higher 6-year 
rate of heart failure (10.2% vs the diuretic group) and of 
hospitalized or fatal heart failure (8.4%). Lisinopril was 
associated with a 10% higher risk of DCM and a 19% higher 
risk for heart failure. Five-year systolic blood pressure was 
significantly higher in the amlodipine group (0.8 mm Hg; 
P = 0.03), and lisinopril (2 mm Hg; P , 0.001) groups, 
compared with chlorthalidone. Thus, thiazide-type diuretics Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
894
Voulgari et al
should be   considered first for antihypertensive treatment and 
for patients who cannot be treated with diuretics; calcium 
channel blockers and ACE inhibitors could be considered as 
alternative choices.158
A double-blind, randomized, 2 × 2 factorial study, the 
Heart Outcomes Prevention Evaluation (HOPE) study, com-
pared an ACE inhibitor, ie, ramipril, vs placebo in preventing 
death from cardiovascular causes, myocardial infarction, or 
all-cause death. The study concluded that ramipril signifi-
cantly reduced the rates of death (6.1% compared with 8.1% 
in the placebo group), myocardial infarction (9.9% vs 12.3%), 
and all-cause mortality (10.4% vs 12.2%). Moreover, ramipril 
therapy significantly decreased the rate of heart failure (9% 
vs 11.5% in the placebo group) and of DCM (6.4% vs 7.6%; 
P = 0.03). Ramipril achieved a significant reduction in the 
new cases with diabetes in the high-risk population included 
in the study, with unknown myocardial dysfunction (low 
ejection fraction) or heart failure.159
The association between major cardiovascular events and 
the achievement of different blood pressure targets during 
antihypertensive therapy, as well as the addition of low doses 
of acetylsalicylic acid was assessed in another randomized 
trial. Felodipine (5 mg/d) was given as baseline therapy, 
and other agents were added according to a 5-step regimen. 
The lowest incidence of DCM and major cardiovascular 
morbidity and mortality occurred in the blood pressure target 
group of #135/80 mm Hg. DCM was reduced by 51%, and 
the addition of acetylsalicylic acid further achieved a 15% 
reduction in major cardiovascular morbidity and a 36% 
reduction in myocardial infarction. The study demonstrated 
that active lowering of blood pressure is particularly ben-
eficial in patients with diabetes and that addition of a small 
dose of acetylsalicylic acid, provided that blood pressure 
is well controlled and the risk of gastrointestinal and nasal 
bleeding is carefully assessed, further reduces the risk of 
acute myocardial infarction.160
A double-masked, randomized, parallel-controlled 
group trial determined the effectiveness of losartan, a 
selective angiotensin II type 1 (AT1) receptor antagonist 
in   comparison with the β-blocker atenolol in reducing 
cardiovascular morbidity and mortality in diabetes patients 
with hypertension and LV hypertrophy. Losartan was more 
effective than atenolol in reducing cardiovascular morbidity 
and mortality (76% reduction of the relative risk of a pri-
mary cardiovascular end point). The greater cardiovascular 
protection of losartan was attributed mainly to the result of 
a more pronounced protection against the detrimental effects 
of angiotensin II.161
A randomized controlled trial, further determined the 
effectiveness of tight blood pressure control (,150/85 mm Hg) 
with the use of an ACE inhibitor (captopril) or a β-blocker 
(atenolol) as main treatment in the reduction of cardiovascular 
morbidity and mortality. Reduction in cardiovascular risk by 
24% in all end points related to diabetes was achieved with 
tight blood pressure control (32% in deaths). In addition, there 
was a 56% reduction in the risk of heart failure.162
Microalbuminuria heralds a further increase in risk of 
myocardial infarction and necessitates even stricter blood 
pressure control. A randomized control trial determined that 
blood pressure lowering with captopril and atenolol is equally 
effective and safe in reducing the risk of fatal and nonfatal 
macrovascular and microvascular complications in patients 
with type 2 diabetes.163 ACE inhibitors largely remain in 
the antihypertensive class of choice, as their use delays the 
progression of nephropathy.164
Medical management of cardiovascular 
disease in diabetes
Heart failure is also conventionally managed with diuretics 
and ACE inhibitors. Certain β-blockers, such as carvedilol, 
are among the drugs of choice for patients with diabetes, due 
to the fact that it has a beneficial effect on insulin resistance 
and a neutral activity on the lipid profile of patients with 
diabetes.165,166 The results of the intervention studies for the 
prevention of DCM are summarized in Table 2.
Struggling toward additional 
knowledge
Targeting the pathophysiological 
substrate: new experimental therapies, 
regimens, and remedies
Recently, direct correlations between apelin plasma levels 
and the structural and functional alterations, ie, LV hypertro-
phy and pressure overload, were demonstrated in humans and 
diabetic rats with DCM. A parallel study was conducted in 
streptozotocin-induced diabetic rats, where pressure overload 
was established by suprarenal aortic banding, as well as in 
patients with diabetes, where during surgery for aortic and 
mitral stenosis, LV function and structure were evaluated 
by 2DE and LV endomyocardial biopsies were procured. 
In both situations, the myocardial expression of apelin was 
significantly downregulated by pressure overload and apelin 
plasma levels were accordingly elevated. Since activation 
of the apelinergic system has a direct positive inotropic and 
vasodilatation effect, it was concluded that elevation in apelin Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Table 2 Major studies on treatment strategies of diabetic cardiomyopathy
Reference Type  
of diabetes
Intervention Purpose Follow-up  
period
Treatment regimen Results
[145] 2 Diet/exercise ↓ incidence  
of DCM
6 y Control (n = 195)  
vs exercise (n = 211)  
vs diet + exercise (n = 194)
33% ↓ in the diet group 
47% ↓ in the exercise group 
38% ↓ in the diet + exercise
[146,147] 2/iGT Behavioral diet +  
physical therapy
↓ onset of diabetes  
↓ DCM incidence
3.2 y individualized counseling 
vs general oral and written 
information about diet/
exercise
58% ↓ in the intervention 
group of diabetes  
56% ↓ in the intervention 
group of DCM
[149] 2, newly  
diagnosed
Prolonged dietary 
management
↓ DCM incidence 
↓ of cardiovascular 
mortality
10 y Diet alone (n = 219) vs 
diet + tolbutamide  
500 mg/metformin  
twice a day (n = 140) vs 
insulin (n = 73)
1.04 RR for Mi per  
↑ 1 mmol/L in fasting plasma 
glucose, no difference 
between treatments for  
the risk of Mi
[150] 2, newly  
diagnosed
Intensified health  
education
↓ Mi incidence  
↓ all-cause  
mortality
11 y a. Usual care (n = 378) vs  
b. intensified health  
education (n = 334)  
vs b + 1.6 clofibric  
acid/day (n = 332)
15.2% patients suffered 
from Mi and 19.2% died, 
postprandial glucose levels 
were independent risk 
factors for CVD death
[152] 2 none evaluation of 
hyperglycemia 
exposure to the 
incidence of DCM
10 y Not applicable each 1% ↓ in HbA1c was 
associated with:  
14% ↓ in risk for Mi  
16% ↓ in risk for HF
[153] 2 Simvastatin  
20 to 40 mg
Prevention of 
recurrent CVD  
in DCM
5.4 y Placebo vs simvastatin  
20 to 40 mg per day
55% ↓ in CVD risk
[154] 2 Gemfibrozil  
1,200 mg/day
Changes in plasma 
lipids could reduce 
major CVD events
7 y Placebo (n = 1.267)  
vs gemfibrozil  
1,200 mg/day  
(n = 1.264)
22%↓ of CVD events for 
every 5 mg/dL ↑ in HDL-C, 
there was an 11% ↓ in CVD 
events
[155] 2 Gemfibrozil  
1,200 mg/day
Efficacy of  
gemfibrozil in  
varying glucose  
levels association 
between 
hyperglycemia  
and CVD risk
7 y Placebo (n = 1.267)  
vs gemfibrozil  
1,200 mg/day  
(n = 1.264)
Fasting insulin $ 271 pmol/L 
was associated with:  
31% ↑ CVD risk  
41% ↓ in CVD death
[158] 2 Diuretic or  
Ca-blocker or ACE
Differences in 
CVD risk between 
antihypertensive 
regiments
4.9 y Diuretic (chlorthalidone  
12.5 to 25 md/d, n = 15.255)  
or Ca-blocker (amlodipine  
2.5 to 10 mg/d, n = 9.048),  
or ACe inhibitor (lisinopril  
10 to 40 mg/d, n = 9.054)
10.2% ↑ risk of HF with 
amlodipine  
19% ↑ risk of HF with 
lisinopril  
33.3% ↑ risk of DCM with 
lisinopril, better blood 
pressure control with 
chlorthalidone
[159] 2 Ramipril  
10 mg/day
Prevention death  
from CVD, MI, all-
cause mortality, HF, 
DCM, development  
of diabetes
5 y Placebo (n = 4.652) vs 
ramipril (n = 4.645)
6.1% ↓ of CVD death  
9.9% ↓ of Mi  
10.4% ↓ of all-cause death 
9% ↓ of HF  
6.4% ↓ of DCM  
3.6% ↓ in new diabetes
[160] 2 Felodipine  
5 mg/day
Achievement of 
blood pressure 
targets with the 
addition of ASA  
and association to 
DCM and CVD risk
3.8 y Felodipine 5 mg/d +  
ASA vs felodipine 
5 mg/d + placebo
51% ↓ of CVD risk in target 
#135/80 mm Hg + 
15% ↓ of CVD risk with 
ASA and 36% ↓ in Mi
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plasma levels may represent a compensatory mechanism 
to maintain inotropism and cardiac output during pressure 
overload conditions, such as DCM.167
The kinins are vasoactive peptides and part of the 
kallikrein–kinin system (KKS). Recent studies have demon-
strated that they are involved in different aspects of remod-
eling, inflammation, and angiogenesis. It is increasingly 
recognized that the KKS is involved in the inflammatory 
processes of the heart. Evidence shows that the KKS has 
beneficial effects in myocardial diseases by protecting from 
inflammation, fibrosis, and apoptosis. KKS also shows a 
proinflammatory character by increasing the production of 
cytokines and stimulating the migration of immune cells. 
Novel important actions of the KKS contribute to neovas-
cularization and recruitment of endothelial progenitor cells 
in ischemic areas and endothelial dysfunction. All these 
evidence support that the KKS could constitute a potential 
therapeutic target in the treatment of myocardial ischemia 
and DCM.168
As previously discussed,47 a significant role in the myo-
cardial dysfunction of DCM is supported by the reduction 
of the sarcoplasmic calcium ATPase myocardial expression 
(SERCA2). Resveratrol, a potent activator of the cardiac 
function and the SERCA2 in type 1 diabetes were recently 
administered to adult male streptozotocin-induced diabetic 
mice, where the induced diabetes produced a progressive 
decline in cardiac function associated with markedly reduced 
SERCA2 and increased collagen deposition. Resveratrol treat-
ment to these mice had a tremendous beneficial effect both in 
terms of improving SERCA2 expression and cardiac function. 
The data demonstrate that in DCM, where the expression of 
SERCA2 is reduced, resveratrol enhances the expression of 
the SERCA2 and improves cardiac function.169
Cardiac fibrosis and protein O-glycosylation are elevated 
in DCM.22,23 One in vitro study in rat cardiac fibroblasts 
recently demonstrated that long-term glucose load sig-
nificantly increases collagen expression. Treatment with 
glucosamine not only induced the collagen expression but 
also increased the O-glycosylated protein. These results 
suggest that O-glycosylation of protein modifies collagen 
expression and, therefore, contributes to DCM.170 ROSs play 
an important role in the development of DCM.42,43 Matrix 
metalloproteinase 2 (MMP-2) is activated by ROS and con-
tributes to the acute loss of myocardial contractile function by 
targeting and cleaving susceptible proteins including troponin 
I and α-actinin. Using the streptozotocin-induced diabetic rat 
model, one study evaluated the 4-week administration effect 
on heart function of a daily in vivo administration of sodium 
selenate (0.3 mg/kg) or a pure ω-3 fish oil with antioxidant 
vitamin E (ω-3E, 50 mg/kg). Both treatments prevented the 
diabetes-induced functional changes; however, the improve-
ment in myocardial function was greater with sodium selenate 
compared with that of the omega-3E. Moreover, these treat-
ments reduced the diabetes-induced increase in myocardial 
oxidized protein sulfhydryl and nitrite concentrations. The 
diabetes-induced changes in myocardial levels of MMP-2 
were associated with a significant reduction in troponin I 
and α-actinin protein levels in both treatment groups. These 
results suggest that diabetes-induced alterations in MMP-2 
contribute to myocardial contractile dysfunction by   targeting 
Table 2 (Continued)
Reference Type  
of diabetes
Intervention Purpose Follow-up  
period
Treatment regimen Results
[161] 2 Losartan  
50 to 100 mg/d
↓ of CVD risk with 
losartan vs  
atenolol
4.7 y Losartan 50–100 mg/d 
(n = 586) vs atenolol 
50–100 mg/d (n = 609)
76% ↓ of relative CVD risk
[162] 2 Blood pressure  
control  
,150/80 mm Hg
↓ of CVD risk 8.4 y Captopril (50–100 mg/d, 
n = 400) vs atenolol 
(50–100 mg/d, n = 358)
24% ↓ of CVD risk  
32% ↓ of death  
56% ↓ of HF
[164] 2 irbesartan 300 mg/d vs 
amlodipine 10 mg/d
↓ of blood pressure 
provides protection 
against progression 
of nephropathy
2.6 y irbesartan (300 mg/d, 
n = 579) vs amlodipine 
(10 mg/d, n = 567)  
vs placebo
with irbesartan:  
37% ↓ risk of doubling 
serum creatinine  
23% ↓ risk of end-stage 
renal disease  
23% ↓ risk of HF
[166] 2 Clopidogrel 300 mg/d  
bolus, followed by 
clopidogrel 75 mg/d  
for 3–12 mo
↓ of CVD mortality 1 y Clopidogrel 300 mg/d  
bolus, followed by  
clopidogrel 75 mg/d  
for 3–12 mo vs placebo
15% ↓ of Mi rate
Abbreviations: DCM, diabetic cardiomyopathy; iGT, impaired glucose tolerance; RR, relative risk; Mi, myocardial infarction; CVD, cardiovascular disease death; HF, heart 
failure; HDL-C, high density lipoprotein-cholesterol levels; Ca-blocker, calcium channel blocker; ACE, angiotensin-converting-enzyme; ASA, acetylsalicylic acid.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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troponin I and α-actinin and that sodium selenate or 
  omega-3E could have therapeutic benefits in DCM.171
Another study also aimed at the suppression of mito-
chondrial oxidative stress and mitochondrion-dependent 
myocardial apoptosis with the administration of antioxidant 
α-lipoic acid (α-LA) to prevent evolution of DCM. In a 
streptozotocin-induced diabetic rat model, α-LA was admin-
istered (100 mg/kg intraperitoneally per day) for 12 weeks. 
Antioxidant α-LA effectively attenuated mitochondrion-
dependent cardiac apoptosis and exerted a protective role 
against the development of DCM. The ability of α-LA to 
suppress mitochondrial oxidative damage was concomitant 
with an enhancement of manganese superoxide dismutase 
activity in the myocardial mitochondria and an increase in 
the glutathione content of myocardial mitochondria.172
The diabetic heart is resistant to ischemic   preconditioning 
because of diabetes-associated impairment of phosphati-
dylinositol 3-kinase (PI3K)-Akt signaling. One study 
  examined the hypothesis that phosphorylation of Janus kinase 
2 (Jak2) upstream of PI3K is impaired in diabetic hearts by 
an AT1 receptor-mediated mechanism. Thus, in a type 2 
diabetic rat model, myocardial infarct was produced. Eryth-
ropoietin (EPO) administration activated the Jak2-mediated 
signaling and limited the infarct size in experimental rats. 
Where EPO failed to induced infarct size limitation, blockade 
of the AT1 receptor by valsartan or losartan treatment for 
2 weeks restored the myocardial response to EPO. Further-
more, treatment with valsartan normalized the calcineurin 
activity in diabetic rats. These results suggest that the 
diabetic heart is refractory to protection by Jak2-activating 
ligands because of AT1 receptor-mediated upregulation of 
calcineurin activity.173
The β isoform of protein kinase C (PKC-β) is a target 
implicated in diabetic complications. To investigate the 
influence of breviscapine on the cardiac structure and func-
tion in rats with DCM, as well as the expression of PKC and 
Ca2+ cycling proteins, type 2 diabetic rats were treated with 
breviscapine for 6 weeks, and invasive cardiac function and 
echocardiographic parameters were measured, while heart 
tissue was obtained for electron microscope study. Treat-
ment with breviscapine reversed the cardiac dysfunction and 
structure changes in rats with DCM, decreased the expression 
of PKC, and increased the expression of calcium handling 
regulators, ie, protein phosphatase inhibitor-1, phospho-
lamban, and SERCA2. This study showed that breviscapine 
has a protective effect on DCM, which is dose related.174 
Breviscapine also prevented cardiac hypertrophy in diabetic 
rats by inhibiting the expression of PKC, which may have a 
protective effect in the pathogenesis of DCM via the PKC/
NF-κB/c-fos signal transduction pathway.175
Using a hemodynamically validated rodent model of 
diabetic diastolic heart failure, the (mRen-2)27 transgenic 
rat another study further determined the selective inhibition 
of PKC-β. Preservation of cardiac function and reduction of 
structural injury were evaluated. Diabetic rats were random-
ized to receive either vehicle or the PKC-β inhibitor, ruboxis-
taurin (20 mg/kg/day) and followed for 6 weeks. Compared 
with untreated animals, ruboxistaurin-treated diabetic rats 
demonstrated preserved systolic and diastolic function. Col-
lagen deposition and cardiomyocyte hypertrophy were both 
reduced in diabetic animals treated with ruboxistaurin as was 
phosphorylated-Smad2, an index of transforming growth 
  factor β (TGF-β) activity. PKC-β inhibition attenuated dia-
stolic dysfunction, myocyte hypertrophy, and collagen depo-
sition and preserved cardiac contractility. PKC-β inhibition 
may represent a novel therapeutic strategy for the prevention 
of diabetes-associated cardiac dysfunction.176
Studies have shown that caffeic and ellagic acid, 2 phe-
nolic acids naturally occurring in many plant foods, can 
provide triglyceride-lowering, anticoagulatory, antioxidative, 
and anti-inflammatory protection in cardiac tissue of diabetic 
mice. Thus, the supplement of these agents might be helpful 
for the prevention or attenuation of DCM.177
Total aralosides of Aralia elata (Miq) Seem (TASAES) 
from the Chinese traditional herb Longya Aralia chinensis L. 
has been demonstrated to improve cardiac function. A recent 
study determined the protective effects of TASAES on DCM 
in streptozotocin-induced diabetic rats. Diabetic rats were 
treated with TASAES for 8 weeks. Cardiac function was 
evaluated by in situ hemodynamic measurements. TASAES 
showed a significant protection against diabetes-induced 
cardiac dysfunction and enhanced the amplitude of Ca2+ 
channel currents. Moreover, histological staining indicated a 
significant inhibition of diabetes-caused pathological changes 
and upregulation of profibrotic factor, and connective tis-
sue growth factor, and expression. The results suggest that 
TASAES prevents diabetes-induced cardiac dysfunction and 
pathological damage.178
The effects of Ginkgo biloba extract (EGb 761), a radical 
scavenger, against diabetes-induced myocardial interstitium 
and microvasculature damage and against additional ischemia 
or reperfusion injury in spontaneously diabetic   BioBreeding/
Ottawa Karlsburg (BB/OK) rats modeling diabetic car-
diac infarction were also investigated as an alternative 
  antioxidative therapy. Pretreatment of diabetic myocardium 
with EGb resulted in an improvement of impaired endothe-Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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lial-dependent vasodilatation in diabetes and additional 
ischemia or reperfusion, diminished mast cell and substance P 
accumulation, and better preserved myocardial ultrastructure 
compared with unprotected myocardium. EGb may act as a 
potent therapeutic adjuvant in patients with diabetes with 
respect to ischemic myocardial injury and may contribute to 
preventing late complications in DCM.179 Another study, also 
demonstrated EGb as a promising adjuvant therapeutic drug 
in patients with diabetes with respect to ischemic myocardium 
injury. It concluded that it may contribute to the prevention 
of late diabetic complications in DCM.180
Natural medicine for the treatment of DCM was further 
recognized by the demonstration of grape seed proantho-
cyanidin extracts (GSPEs) as therapeutic agents against 
DCM in streptozotocin-induced diabetic rats. GSPEs 
decreased AGEs and ameliorated glycation-associated 
cardiac damage.181
Recent studies in mice experimental models with acute 
ischemic injury revealed that EPO has numerous tissue-
protective effects in the heart, brain, and kidneys. One study 
explored the tissue-protective properties of chronic EPO 
treatment in an experimental model of the db/db mouse with 
diabetic heart injury. Continuous erythropoietin receptor 
activator (CERA)-treated mice had a significant reduction in 
TGF-β1 and collagen I expression in cardiac tissue. Atrial 
natriuretic peptide expression was increased in CERA-treated 
mice. Chronic treatment with CERA protects cardiac tissue in 
diabetic animals by inhibiting molecular pathways of cardiac 
fibrosis, and the effects are dose dependent.182
Cell-based myocardial  
regenerative therapy
Cell-based myocardial regenerative therapy can be poten-
tially applied in the treatment of DCM in order to limit the 
consequences of decreased contractile function and compli-
ance of damaged ventricles, owing to ischemic and nonisch-
emic myocardial areas. A variety of myogenic and angiogenic 
cell types have been proposed, such as skeletal myoblasts, 
mononuclear and mesenchymal bone marrow cells, circu-
lating blood-derived progenitors, adipose-derived stromal 
cells, induced pluripotent stem cells, umbilical cord cells, 
endometrial mesenchymal stem cells, adult testis pluripotent 
stem cells, and embryonic cells. It is important to note that 
stem cells are not an alternative to heart transplantation; 
selected patients should be in an early stage of heart fail-
ure, as the goal of this regenerative approach is to avoid or 
delay organ transplantation. Since the cell niche provides 
crucial support needed for stem cell maintenance, the most 
  interesting and realistic perspectives include the association 
of intramyocardial cell transplantation with tissue-engineered 
scaffolds and multisite cardiac pacing in order to transform 
a passive regenerative approach into a “dynamic cellular 
  support,” a promising method for the creation of “bioartificial 
myocardium”.183
Conclusion
DCM is not uncommon and is associated with increased 
morbidity and mortality in patients with diabetes. Meta-
bolic pathway deregulation in diabetes adversely affects 
the cardiac myocytes, as well as every cellular element 
within the vascular walls. Other pathogenetic mechanisms 
involved in decreasing myocardial contractility in DCM 
are impaired calcium homeostasis, renin–angiotensin 
system upregulation, increased oxidative stress, altered 
substrate metabolism, and mitochondrial dysfunction.184 
Continued research has provided novel insights into under-
lying molecular and pathophysiological mechanisms that 
increase the vulnerability of the diabetic heart to failure.185 
The choice of antidiabetic medication may influence the 
cardiovascular outcome.186,187 However, intensive treatment 
of the gamut of metabolic abnormalities associated with 
diabetes beyond hyperglycemia reduces the rates of DCM, 
myocardial infarction, and associated cardiovascular death. 
As this high-risk population increases, elucidation of the 
mechanisms responsible for DCM will further motivate 
the generation of novel therapies tailored to decrease the 
cardiovascular morbidity and mortality in diabetes. Strate-
gies to encourage the aggressive use of targeted medical 
therapies will further reduce the magnified rates of the 
diabetic heart failure burden.
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